Biogen is an American biotech company based in Cambridge, Massachusetts. The company uses recombinant DNA technology, also known as biotechnology. This makes it possible to produce human proteins and therefore medicinal products with the help of microorganisms. The company continues to develop new substances and works on improving already approved molecules.
According to Biogen's latest financial reports the company's total assets are โน2.397 Trillion. A companyโs total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
Year | Total assets | Change |
---|---|---|
2024-12-31 | โน2.406 T | 7.67% |
2023-12-31 | โน2.234 T | 9.99% |
2022-12-31 | โน2.031 T | 14.33% |
2021-12-31 | โน1.777 T | -1.29% |
2020-12-31 | โน1.800 T | -7.29% |
2019-12-31 | โน1.942 T | 9.83% |
2018-12-31 | โน1.768 T | 17.09% |
2017-12-31 | โน1.510 T | -2.85% |
2016-12-31 | โน1.554 T | 19.94% |
2015-12-31 | โน1.296 T | 42.87% |
2014-12-31 | โน907.23 B | 23.78% |
2013-12-31 | โน732.91 B | 32.14% |
2012-12-31 | โน554.65 B | 15.86% |
2011-12-31 | โน478.72 B | 32.02% |
2010-12-31 | โน362.62 B | -8.61% |
2009-12-31 | โน396.80 B | -2.63% |
2008-12-31 | โน407.54 B | 20.35% |
2007-12-31 | โน338.63 B | -10.6% |
2006-12-31 | โน378.80 B | 0.43% |
2005-12-31 | โน377.17 B | -4.98% |
2004-12-31 | โน396.95 B | -8.27% |
2003-12-31 | โน432.71 B | 338.1% |
2002-12-31 | โน98.77 B | 18.94% |
2001-12-31 | โน83.04 B |